Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.
Miller
Michael
M
University of Maryland Medical Center, Baltimore, MD, USA. mmiller@heart.umaryland.edu
D000368:Aged; D001629:Bezafibrate / Q000627:therapeutic use*; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D015994:Incidence; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate